Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals
NCT ID: NCT01040104
Last Updated: 2013-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the young, damage to an organ mostly triggers fully regenerative mechanisms called "primary" wound healing. Repeated damage in young individuals may cause "secondary" wound healing eg. scar formation reflecting a rescue program, in which reorganisation has failed.
Organ failure in the ageing organism is characterized by a progressive loss of its capability to achieve an orderly reactivation of organ repair, and results in a combination of chronic inflammation and fibroproliferative, non-regenerative repair affecting several organs, including lung, liver and skin.
RESOLVE's objective is to identify, characterize, and validate molecular targets responsible for shifting primary organ repair towards fibroproliferative wound healing as a result of an age-dependent loss of regulatory control.
The structured approach is based on
* different forms of wound healing,
* different human diseases and
* different genetic backgrounds,
aiming to provide future diagnostic tools in various organs, to create transgenic animal test systems, and to identify molecular targets involved in fibroproliferative wound healing.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
WP 2.1: Regular skin repair
In elective plastic surgery most excised operative skin specimens are usually discarded, and represent an excellent opportunity of harvesting skin biopsies without additional invasive measures. This work package analyzes skin samples of individuals after elective plastic surgery with normal wound healing serving as control group.
WP 2.2: Skin repair with and without hypertrophic scar formation
A classic example of fibroproliferative repair in the skin is hypertrophic scarring classified as a dermal skin lesion, which is raised above skin level, stays within the confines of the initial wound and increases in size by pushing out the margins of the scar without invading the surrounding normal tissue.
Hypertrophic scarring is a condition commonly observed after burns and in regions of prolonged wound healing (\>21 days). The underlying pathology of hypertrophic scarring, however, is poorly understood. Hypertrophic scars can be managed conservatively, and only require surgical intervention under special circumstances.
This work package analyzes the clinical and molecular response to a standard treatment regimen in skin regions with and without hypertrophic scars after skin injuries.
WP 2.4: Wound healing in normal and diabetic individuals
Diabetes mellitus is a known factor to cause impaired wound healing. Due to microangiopathic, macroangiopathic and other conditions resulting from atherosclerosis and peripheral neuropathy wound healing in diabetic individuals is usually delayed (hypotrophic, atrophic) and often complicated by immunosuppression and superinfections. The rising prevalence of diabetes mellitus in the elderly population makes it necessary to understand its related processes in relevant clinical wound models.
Split-thickness skin-grafting is a commonly applied technique in plastic surgery, and donor sites of previously uninjured skin regions spontaneously heal within two weeks, representing an ideal condition to monitor clinical and molecular changes in diseased vs. non-diseased states.
This work package analyzes skin repair in donor sites of split-thickness skin grafts in non-diabetic and diabetic individuals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regular wound healing, young
Regular skin repair, controlled wound healing conditions in young individuals
Skin sample
Taken from regularly discarded tissue during routine operation
Blood taking
Blood taking on day 0
Regular wound healing, aged
Regular skin repair, controlled wound healing conditions in aged individuals
Skin sample
Taken from regularly discarded tissue during routine operation
Blood taking
Blood taking on day 0
Hypertrophic scarring, young
Skin repair with and without hypertrophic scarring in young individuals
Skin biopsy
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Hypertrophic scarring, aged
Skin repair with and without hypertrophic scarring in aged individuals
Skin biopsy
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Non-diabetic, young
Skin repair in non-diabetic young individuals
Skin biopsy
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Non-diabetic, aged
Skin repair in non-diabetic aged individuals
Skin biopsy
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Diabetic, young
Skin repair in young diabetic individuals
Skin biopsy
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Diabetic, aged
Skin repair in aged diabetic individuals
Skin biopsy
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Skin sample
Taken from regularly discarded tissue during routine operation
Skin biopsy
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Skin biopsy
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Blood taking
Blood taking on day 0
Blood taking
Blood taking on day 90
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-45 and 55-85 years, respectively
* normal and/or hypertrophic scars
* Baux score \<100
* age 18-45 and 55-85 years, respectively
Exclusion Criteria
* cardiac disease adversely affecting peripheral blood flow
* active neoplastic disease
* immunosuppressive condition, congenital or acquired
* anemia
* autoimmune disorder
* acute or chronic renal failure
* liver cirrhosis or active hepatitis
* active substance-abuse disorder
* severe underweight (body mass index \<16)
* endocrinological disorder
* pregnancy or lactation for women of child-bearing age
WP2.2
* sepsis
* electrical and/or chemical burn
* clinically significant wound infection in areas of planned biopsies
* cardiac disease adversely affecting peripheral blood flow
* active neoplastic disease
* immunosuppressive condition, congenital or acquired
* autoimmune disorder
* acute or chronic renal failure
* liver cirrhosis or active hepatitis
* active substance-abuse disorder
* severe underweight (body mass index \<16)
* endocrinological disorder
* pregnancy or lactation for women of child-bearing age
WP 2.4
* cardiac disease adversely affecting peripheral blood flow
* active neoplastic disease
* immunosuppressive condition, congenital or acquired
* anemia
* autoimmune disorder
* acute or chronic renal failure
* liver cirrhosis or active hepatitis
* substance-abuse disorder
* severe underweight (body mass index \<16)
* thyroid function disorder
* pregnancy or lactation for women of child-bearing age
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Union
OTHER
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Lumenta, MD
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars P Kamolz, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
MUW
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Plastic and Reconstructive Surgery, Department of Surgery, Medical University of Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gangemi EN, Gregori D, Berchialla P, Zingarelli E, Cairo M, Bollero D, Ganem J, Capocelli R, Cuccuru F, Cassano P, Risso D, Stella M. Epidemiology and risk factors for pathologic scarring after burn wounds. Arch Facial Plast Surg. 2008 Mar-Apr;10(2):93-102. doi: 10.1001/archfaci.10.2.93.
Izadi K, Ganchi P. Chronic wounds. Clin Plast Surg. 2005 Apr;32(2):209-22. doi: 10.1016/j.cps.2004.11.011.
Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med. 2006 Jun;23(6):594-608. doi: 10.1111/j.1464-5491.2006.01773.x.
Komesu MC, Tanga MB, Buttros KR, Nakao C. Effects of acute diabetes on rat cutaneous wound healing. Pathophysiology. 2004 Oct;11(2):63-67. doi: 10.1016/j.pathophys.2004.02.002.
Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999 Oct;104(5):1435-58. doi: 10.1097/00006534-199910000-00031. No abstract available.
Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg. 1989 Nov;84(5):827-37. doi: 10.1097/00006534-198911000-00021. No abstract available.
Gottrup F, Agren MS, Karlsmark T. Models for use in wound healing research: a survey focusing on in vitro and in vivo adult soft tissue. Wound Repair Regen. 2000 Mar-Apr;8(2):83-96. doi: 10.1046/j.1524-475x.2000.00083.x.
Ashcroft GS, Mills SJ, Ashworth JJ. Ageing and wound healing. Biogerontology. 2002;3(6):337-45. doi: 10.1023/a:1021399228395.
Gosain A, DiPietro LA. Aging and wound healing. World J Surg. 2004 Mar;28(3):321-6. doi: 10.1007/s00268-003-7397-6. Epub 2004 Feb 17.
Crooks A. How does ageing affect the wound healing process? J Wound Care. 2005 May;14(5):222-3. doi: 10.12968/jowc.2005.14.5.26777.
Deitch EA, Wheelahan TM, Rose MP, Clothier J, Cotter J. Hypertrophic burn scars: analysis of variables. J Trauma. 1983 Oct;23(10):895-8.
Bombaro KM, Engrav LH, Carrougher GJ, Wiechman SA, Faucher L, Costa BA, Heimbach DM, Rivara FP, Honari S. What is the prevalence of hypertrophic scarring following burns? Burns. 2003 Jun;29(4):299-302. doi: 10.1016/s0305-4179(03)00067-6.
Oliveira GV, Chinkes D, Mitchell C, Oliveras G, Hawkins HK, Herndon DN. Objective assessment of burn scar vascularity, erythema, pliability, thickness, and planimetry. Dermatol Surg. 2005 Jan;31(1):48-58. doi: 10.1111/j.1524-4725.2005.31004.
Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, Stella M, Teot L, Wood FM, Ziegler UE; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg. 2002 Aug;110(2):560-71. doi: 10.1097/00006534-200208000-00031.
Related Links
Access external resources that provide additional context or updates about the study.
Ethics Committee of the Medical University of Vienna and the Vienna General Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MUW-EK-Nr_015/2009
Identifier Type: OTHER
Identifier Source: secondary_id
FP7-202047.WP.2.1-2.2-2.4
Identifier Type: -
Identifier Source: org_study_id